May 23, 2017 11:33 am UTC| Business
Contribution of single agents in the combination regimen successfully established pursuant to the UNITY-CLL Special Protocol Assessment; DSMB recommends no further enrollment to single agent arms DSMB reviewed updated...
May 23, 2017 11:33 am UTC| Business
CARMIEL,Israel, May 23, 2017 -- Protalix BioTherapeutics, Inc.(NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa...
May 23, 2017 11:33 am UTC| Business
CARMIEL,Israel, May 23, 2017 -- Protalix BioTherapeutics, Inc.(NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa...
May 23, 2017 11:33 am UTC| Business
CARMIEL,Israel, May 23, 2017 -- Protalix BioTherapeutics, Inc.(NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa...
May 23, 2017 11:33 am UTC| Business
CARMIEL,Israel, May 23, 2017 -- Protalix BioTherapeutics, Inc.(NYSE:PLX) (TASE:PLX), announced today that an oral presentation highlighting the results from the Company’s phase II clinical trial of alidornase alfa...
May 23, 2017 11:32 am UTC| Business
- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017 - Actinium is a sponsor of the conference being held May 30th - June 2nd , 2017 at...
May 23, 2017 11:32 am UTC| Business
- Data from the Company’s Actimab-A program to be presented in the Clinical Experiences session being held on Wednesday, May 31, 2017 - Actinium is a sponsor of the conference being held May 30th - June 2nd , 2017 at...